Table 3:
Development Status for Targeted Therapies in R/R PTCL by Mechanism of Action
| Kinase | Cerdulatinib | Phase I ongoing |
| TAK-659 | ||
| CPI-818 | ||
| Crizotinib | ||
| Ceritinib | ||
| Copanlisib | ||
| Duvelisib | Phase II ongoing | |
| Tenalisib | ||
| Ruxolitinib | ||
| Alisertib | Phase III completed | |
| Epigenetic | Valemetostat | Phase I ongoing |
| Romidepsin + other (multiple) | Phase II ongoing | |
| Azacitidine | Phase III ongoing | |
| Romidepsin alone | Approved | |
| Belinostat | ||
| Other | ALRN-6924 | Phase I completed |
| MCL1 inhibitors | Phase I ongoing | |
| Lenalidomide | Phase II completed | |
| Tipifarnib | Phase II ongoing | |
| Venetoclax |
Finally, the decision regarding consolidating deep responses to targeted therapies with allogeneic stem cell transplantation is complex and should be individualized to each patient’s situation.